Abbott Completes $21 Billion Acquisition of Exact Sciences, Becomes Leader in Cancer Diagnostics

summarizeSummary

Abbott Laboratories has completed its $21 billion acquisition of Exact Sciences, significantly expanding its footprint and leadership in the high-growth cancer diagnostics market.

check_boxKey Events

• Acquisition Completed

  Abbott Laboratories finalized its acquisition of Exact Sciences Corporation on March 23, 2026, for $105.00 per share in cash, following the initial agreement in November 2025.

• Strategic Market Expansion

  This acquisition establishes Abbott as a leader in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments, adding a new growth vertical.

• Enhanced Product Portfolio

  Abbott gains a comprehensive suite of cancer detection and treatment products, including Cologuard, Oncotype DX, Oncodetect, and Cancerguard, along with a robust pipeline.

auto_awesomeAnalysis

Abbott Laboratories has completed its significant acquisition of Exact Sciences Corporation, a strategic move that positions the company as a leader in the rapidly expanding cancer screening and diagnostics market. This $21 billion transaction, initially agreed upon in November 2025 and highlighted in Abbott's recent 10-K, is expected to add a new growth vertical and enhance Abbott's presence in the $60 billion U.S. cancer diagnostics segment. The integration of Exact Sciences' portfolio, including key products like Cologuard and Oncotype DX, provides Abbott with a comprehensive suite of offerings for early cancer detection and personalized treatments. This strategic expansion is a long-term growth driver for Abbott, occurring while the company's stock is trading near its 52-week low, suggesting potential for future upside as the market fully digests the benefits of this acquisition.